Rapport Therapeutics, Inc. (RAPP)
(Delayed Data from NSDQ)
$14.43 USD
+0.39 (2.78%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $14.38 -0.05 (-0.35%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RAPP 14.43 +0.39(2.78%)
Will RAPP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RAPP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for RAPP
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Citizens JMP
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
RAPP: JMP Securities Reiterates Market Outperform Rating with $28 Target | RAPP Stock News
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call